In 2009, the American Cancer Society (ACS) initiated a series of systematic evidence reviews to update recommendations for early prostate cancer detection. The evidence reviews focused on studies of screening, the performance of screening tests, harms associated with testing and therapy for localized prostate cancer, and shared and informed decision making in prostate cancer screening. Based on this evidence, the ACS recommends that asymptomatic men who have at least a 10-year life expectancy have an opportunity to make an informed decision with their health care provider about screening for prostate cancer after receiving information about the uncertainties, risks, and potential benefits associated with prostate cancer screening. Prostate ...
Force (USPSTF) recommendation statement about screening for prostate cancer. Methods: The USPSTF eva...
Background: Population-based screening for prostate cancer (PCa) remains controversial. To help men ...
Introducing screening for prostate cancer requires evidence that this would do more good than harm. ...
In 2009, the American Cancer Society (ACS) initiated a series of systematic evidence reviews to upda...
In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
gen (PSA) in men aged 75 years or older. They concluded that there was insufficient evidence as to t...
Whether to screen for prostate cancer in aging men is a topic that is fairly well researched, but re...
Since 2012, multiple new guidelines have been issued advising changes in screening for prostate canc...
The US Preventive Services Task Force has issued a new draft guideline, with a "C" recommendation th...
men. It rarely causes death in men younger than 50 years; most deaths associated with it occur in me...
The benefits of population-based prostate cancer screening are the detection of clinically important...
OBJECTIVES: To review evidence regarding the potential introduction of prostate cancer screening pro...
Prostate cancer is the most common non-skin cancer in the United States, and the second leading caus...
In American men, prostate cancer is the most common cancer and the second leading cause of cancer de...
Force (USPSTF) recommendation statement about screening for prostate cancer. Methods: The USPSTF eva...
Background: Population-based screening for prostate cancer (PCa) remains controversial. To help men ...
Introducing screening for prostate cancer requires evidence that this would do more good than harm. ...
In 2009, the American Cancer Society (ACS) initiated a series of systematic evidence reviews to upda...
In 2009, the American Cancer Society (ACS) Prostate Cancer Advisory Committee began the process of a...
ImportanceIn the United States, the lifetime risk of being diagnosed with prostate cancer is approxi...
gen (PSA) in men aged 75 years or older. They concluded that there was insufficient evidence as to t...
Whether to screen for prostate cancer in aging men is a topic that is fairly well researched, but re...
Since 2012, multiple new guidelines have been issued advising changes in screening for prostate canc...
The US Preventive Services Task Force has issued a new draft guideline, with a "C" recommendation th...
men. It rarely causes death in men younger than 50 years; most deaths associated with it occur in me...
The benefits of population-based prostate cancer screening are the detection of clinically important...
OBJECTIVES: To review evidence regarding the potential introduction of prostate cancer screening pro...
Prostate cancer is the most common non-skin cancer in the United States, and the second leading caus...
In American men, prostate cancer is the most common cancer and the second leading cause of cancer de...
Force (USPSTF) recommendation statement about screening for prostate cancer. Methods: The USPSTF eva...
Background: Population-based screening for prostate cancer (PCa) remains controversial. To help men ...
Introducing screening for prostate cancer requires evidence that this would do more good than harm. ...